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Abstract 
Background: Nerve growth factor (NGF) is known not only as a major factor for neuronal plasticity but also as a pain 
stimulator. Although there have been several trials with NGF for its application in the regeneration or protection of the 
nervous system, the pain induced by NGF remains a challenge to be overcome. In this study, the pain induced by NGF 
gene therapy was evaluated.
Results: Vehicle or recombinant dog NGF plasmid was administered into the intrathecal space of dogs. Twenty‑four 
hours after the vehicle or NGF plasmid inoculation, dogs were subcutaneously treated with 150 mg/kg pyridoxine 
every day for 7 days. For pain assessment, physical examination and electrophysiological recording were performed. 
Only in the vehicle‑treated group, weight loss occurred, while NGF plasmid inoculation significantly improved this 
physical abnormalities. In the vehicle‑treated group, electrophysiological recordings showed that H‑reflex disap‑
peared at 24 h after the last pyridoxine treatment. However, in the NGF plasmid inoculated group, the H‑reflex were 
normal. In the results of immunohistochemistry, the NGF plasmid administration efficiently expressed in the dorsal 
root ganglia and significantly increased the pyridoxine‑induced reduction of calcitonin gene‑related peptide (CGRP) 
immunoreactive neurons, but not in substance P immunoreactive neurons, in the dorsal root ganglia.
Conclusions: Given these results, we reason that NGF gene therapy in pyridoxine induced neuropathic dogs does 
not induce neuropathic pain with this dosage, even with increasing the expression of CGRP.
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Background
Neurotrophic factors are undoubted stimulators for 
the outgrowth of specific neuronal populations [1, 2]. 
Due to their potency, neurotrophic factors have drawn 
high expectations from scientists and various trials have 
attempted to investigate their efficacy [1]. Among the 
various neurotrophic factors, nerve growth factor (NGF) 
was the first neurotrophic factor discovered [3] and it 
was revealed that it impacts the development and main-
tenance of neurons in the peripheral nervous system and 
the functional integrity of neurons in the central nervous 
system [4]. For this reason, various preclinical characteri-
zations and clinical trials with NGF have been performed 
[2]. In cases of clinical trials with recombinant human 
NGF (rhNGF) on peripheral neuropathies, phase I trials 
have shown that dose-dependent mild to moderate mus-
cle pain and hyperalgesia appeared at the injection site 
as a side effect [5, 6]. Phase II trials of diabetic polyneu-
ropathy indicate that rhNGF significantly improves the 
neuropathic symptoms, but produces dose-dependent 
hyperalgesia at the injection site [7, 8]. Other research 
has also demonstrated that although NGF develops and 
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maintains the peripheral nervous system, it also contrib-
utes to producing hyperalgesia [9–11].
Although the evidence of neuropathic pain with NGF is 
obvious, there are still trials for NGF treatment because 
it has great pharmacological potential for the treatment 
of central neurodegenerative diseases and for peripheral 
neuropathies [2]. Interestingly, although it has been dem-
onstrated that dose-dependent hyperalgesia is present at 
the injection site after a recombinant human NGF sub-
cutaneous injection for peripheral neuropathies [8], there 
were no observable side effects when small amounts of 
NGF were injected through an intra-cerebro-ventricular 
channel for central nervous system diseases [12]. How-
ever, when injections of large amounts of NGF were 
administered, weight loss or back pain was reported even 
though it was administrated intra-cerebro-ventricularly 
[13]. Based on these results, we could understand that the 
route of injection and the amount of NGF being injected 
are important factors for the occurrence of neuropathic 
pain.
Hyperalgesia is a significant symptom for patients with 
neuropathic pain. Neuropathic pain is initiated or caused 
by a primary lesion to, or dysfunction in the nervous sys-
tem [14]. Neuropathic pain and the dorsal root ganglion 
(DRG) are closely linked with each other. It is evident 
that hyperexcitability of DRG neurons is an important 
component for neuropathic pain [15]. The DRG neu-
rons contain several kinds of peptides, which are related 
to various sensations [16]. Especially in the DRG, many 
small-diameter neurons are nociceptive and possess neu-
ropeptides such as substance P (SP) and calcitonin gene-
related peptide (CGRP), which are released in response 
to noxious simulation, are the main peptides for nocic-
eption [17]. It has been discovered that NGF-sensitive, 
tyrosine kinase receptor A (trkA) participates in pain 
processing and that neurons labeled with trkA overlap 
with neurons labeled with SP and CGRP [12, 13].
Sensory neuropathies, which is one of the peripheral 
neuropathies, are frequently associated with diabetes or 
anticancer therapies and less frequently associated with 
vitamin deficiency, hypothyroidism, uremia, and inher-
ited metabolic disorders [18, 19]. Therefore, it is very 
important to develop animal models of sensory neu-
ropathies. There are animal model studies using pyridox-
ine induced peripheral neuropathies [20, 21]. However 
these studies used extreme doses of pyridoxine or took 
a long period of time [22–24]. Chung et al. confirmed a 
dog model of sensory neuropathy by administering sub-
cutaneous injections of pyridoxine over a short period 
of time [25]. This dog model fulfilled the requirement of 
advanced animal models with sensory neuropathies.
Based on these studies, we proposed a hypothesis that 
NGF gene therapy for pyridoxine induced neuropathy 
in dogs [26] could cause hyperalgesia. In this study, for 
identifying the relationship between NGF gene therapy 
and hyperalgesia, pain assessment including physical 
examination and electrophysiological recordings, and the 
changes in SP and CGRP levels were evaluated in dogs 
with pyridoxine-induced neuropathy that were adminis-




The respiration rate (normal range 10–30 breaths/min), 
heart rate (normal range 70–180 breaths/min), rectal 
temperature (normal range 38.0–39.1  °C) and systolic 
arterial blood pressure (normal range 110–140  mmHg) 
of all three groups were within normal ranges during the 
experimental period (Fig.  1). However, weight measure-
ments showed that there was significant weight loss only 
in the vehicle-treated group (p < 0.01), while there were 
no weight changes for the control group and the gene 
therapy group (Fig. 2).
Electrophysiological recording
Electrophysiological readings were recorded to meas-
ure M waves and H-reflexes in all groups before and 
after pyridoxine treatment. The M wave amplitude in 
all groups showed no remarkable change before and 
after the pyridoxine administration (p  >  0.05). In the 
control group, H-reflexes did not change before or after 
pyridoxine injection. However, there was a remarkable 
change in the H-reflex before and after the pyridoxine 
treatment in the vehicle-treated group. Before pyridox-
ine injection, the average amplitude of the H-reflex was 
0.52 ± 0.06 mV. After the pyridoxine injection, however, 
there was no consistently detectable H-reflex in the vehi-
cle-treated group (p < 0.01). The H-reflexes in the NGF 
therapy group slightly decreased after pyridoxine injec-
tion, but significant differences were not detected before 
or after the pyridoxine injection (p > 0.05) (Fig. 3).
Postural reaction assessments
On the postural reaction (hopping, wheelbarrowing, 
extensor postural thrust and proprioceptive position-
ing) assessment, all the dogs in the vehicle-treated group 
developed a neurological disorder, most prominently 
in the hindquarters. In addition, all dogs in this group 
started to show proprioceptive abnormalities involving 
their hindquarters as detected by the postural reaction 
test on the third day of the pyridoxine injections. These 
conditions were maintained until the end of the injec-
tions (p < 0.01). In contrast, all of the dogs in the control 
group and the gene therapy group were normal during 
the postural reaction test (Fig. 4).
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Fig. 1 The respiration rate, heart rate, rectal temperature and systolic arterial blood pressure of all three groups were within normal ranges during 
the experimental period without significantly changes. This results showed that there is no evidence of tachypnea, tachycardia, hypertension, and 
hyperthermia in all group, which are general physiological indicators of pain (n = 4 per group)
Fig. 2 Body weight changes significantly only in the vehicle‑treated group (p < 0.01) after pyridoxine treatment. This result evidences that NGF 
gene therapy in this study alleviated neuropathic pain, protecting the DRG from the neuropathic pain normally produced by pyridoxine (n = 4 per 
group)
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Fig. 3 H‑reflex disappears after the pyridoxine treatment in the vehicle‑treated group (P < 0.01) however, H‑reflexes do not change after the pyri‑
doxine injection in the gene‑treated group. This result evidences that NGF gene therapy in this study alleviated neuropathic pain (n = 4 per group)
Fig. 4 On the postural reaction assessment, all the dogs only in the vehicle‑treated group developed a neurological disorder, most prominently in 
the hindquarters on the third day of the pyridoxine injections. These conditions were maintained until the end of the injections. In contrast, all of 
the dogs in the control group and the gene therapy group were normal during the postural reaction test (n = 4 per group; **P < 0.01)
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Histopathological analysis
Expression of NGF in the DRG
In the vehicle-treated group, NGF-positive neurons 
were barely detected in the DRG of L4, while in the pyr-
idoxine-treated group, many NGF-positive neurons were 
detected in the DRG (Additional file 1: Figure S1).
Neuronal damage in the DRG
In the control group, cresyl violet positive neurons were 
abundantly detected in the DRG of L4 (Fig.  5a). In the 
vehicle-treated group, the presence of large-sized cresyl 
violet positive neurons was significantly decreased and 
those neurons were detected with vacuoles (Fig.  5b). 
In this group, the number of large-sized cresyl violet 
positive neurons was 51.7 % of the control group, while 
small- or medium-sized neurons were similarly detected 
compared to that in the control group (Fig.  5d). In the 
NGF therapy group, large-sized cresyl violet positive 
neurons were abundantly detected, although a few large 
vacuoles were also detected (Fig.  5c). In this group, the 
number of large-sized cresyl violet positive neurons was 
78.1 % of the control group’s amount, while the number 
of medium- and small-sized neurons was not signifi-
cantly different between them (Fig. 5d).
Immunoreactivity for SP and CGRP in the DRG
In the control group, SP immunoreactivity was mainly 
detected in the small- and medium-sized neurons, as 
well as the neuropil (Fig.  6a), while CGRP immunore-
activity was detected in all sized neurons (Fig.  6b). In 
the vehicle-treated group, the number of SP immu-
noreactive neurons was slightly decreased in the DRG 
compared to that in the control group, but the differ-
ence between the groups did not achieve significance 
(Fig. 6c, g). However, the number of CGRP immunore-
active small-, medium-, and large-sized neurons in the 
vehicle-treated group was significantly decreased com-
pared to that in the control group (Fig.  6d, h). For the 
NGF-therapy group, SP immunoreactive neuron detec-
tion was similar to the vehicle-treated group (Fig.  6e, 
g). In contrast, the number of CGRP immunoreactive 
medium- and small-sized neurons was significantly 
greater in the DRG of the therapy group than that in the 
vehicle-treated group (Fig. 6f, h).
Fig. 5 Cresyl violet staining of the dorsal root ganglion (DRG) in the control (a), vehicle‑treated (Vehicle, b), and nerve growth factor gene‑treated 
(NGF, c) groups at 4 weeks after pyridoxine injection for 1 week. In the control group, cresyl violet positive small‑ (white arrow), medium‑ (arrow 
head), and large‑sized (black arrow) neurons are well detected in the DRG. Note that cresyl violet positive cells in the vehicle‑treated group are few 
and some vacuoles are detected, while cresyl violet positive large‑sized neurons are also abundant in the NGF group. Scale bar 100 μm. d Relative 
number as a % of small‑, medium‑, and large‑sized neurons of the control group in the DRG (n = 4 per group; *P < 0.05, significantly different from 
the control group; #P < 0.05, significantly different from the vehicle group). The bars indicate the mean ± SEM
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Discussion
A previous study found a protective effect of NGF gene 
therapy against pyridoxine induced sensory neuropathy 
in a dog model [26]. In this study, the characteristics of 
the pain induced by NGF gene therapy were evaluated 
in the same model. In the present study, we observed the 
significant reduction in the number of large-sized neu-
rons in the DRG after pyridoxine intoxication. This result 
was supported by previous studies that the administra-
tion of pyridoxine selectively causes the damage in the 
large-diameter A-cells of the DRG with larger-diameter 
myelinated fibers in the sciatic nerve [20, 27, 28]. In our 
studies, we also observed the vulnerability of large-sized 
neurons after pyridoxine intoxication in DRG of dogs [25, 
26, 29, 30].
The biological effects of neurotrophins are mediated via 
two major receptors, tyrosine kinase (Trk) receptors and 
75  kDa (p75NTR). Each neurotrophin binds with high 
affinity to a specific Trk receptor. In the case of NGF, it 
has a high affinity to TrkA and a lower affinity to p75NTR 
[31]. Both NGF-trkA signaling and NGF-p75NTR par-
ticipate in the neuropathic pain pathway [32]. NGF-trkA 
signaling dynamically regulates the synthesis of nocicep-
tive neuropeptides like SP and CGRP, which contribute 
to the sensation of neuropathic pain [33]. For the relief of 
pain, there is critical need for drugs other than non-ste-
roidal anti-inflammatory drugs. Based on these concepts, 
there are various trials of NGF antibody which sought to 
block the neuropathic pain, with the results indicating 
NGF antibody as s possible painkiller [29, 30].
For diagnosis and treatment of neuropathic pain, ques-
tionnaires to determine whether the symptoms indicate 
neuropathic pain or not are required, so many kinds of 
questionnaires have been developed for humans [34]. 
There are many trials for scaling pain in animals; how-
ever, there are not any special scales for neuropathic pain 
[35–37]. General physiological indicators of pain are 
tachypnea, tachycardia, hypertension, and hyperthermia. 
Additionally, anorexia resulting in weight loss is common 
in animals with significant acute or chronic pain [38]. 
In this study, there were no changes of respiratory rate, 
heart rate, body temperature or systolic arterial blood 
pressure in all three groups. However significant weight 
loss was confirmed only in the positive control group, 
not in the gene therapy group. This result evidences that 
NGF gene therapy in this study mitigated neuropathic 
pain, protecting the DRG from the neuropathic pain nor-
mally produced by pyridoxine. In this study, the route of 
the intrathecal region was chosen and the single dose of 
40 μg NGF was used in the dog model. The dosage was 
decided by previous papers which used same manufac-
tural cationic polymer transfection reagent to the intrath-
ecal region [39, 40]. Based on the immunohistochemistry 
for NGF, we found that NGF effectively expressed in the 
DRG, which is the damaged area by pyridoxine. We could 
assume that the amount of NGF was not enough to cause 
neuropathic pain, but just enough to protect the DRG 
from the pyridoxine-induced neuropathy.
Unfortunately, though patients with neuropathic pain 
have the same predisposing condition, their responses 
to it could be varied [41]. For the objectification of ana-
lyzing neuropathic pain, the development of diagnostic 
techniques to identify it is necessary. There are a few tri-
als to objectify the pain using the H-reflex. The muscle 
potential is the resultant activity of a true monosynap-
tic reflex arc and thus is appropriately referred to as an 
H-reflex. It has been demonstrated that a decrease in the 
mean H-reflex amplitude was observed in patients with 
back pain [42, 43]. Similarly to those studies, it was also 
confirmed that the H-reflex disappeared only in the posi-
tive control group in this study.
Forty percent of the DRG neurons are large-sized, 
which give rise to myelinated axons. In the present study, 
we observed a reduction in the number of large-sized 
neurons in the DRG after pyridoxine injection. This result 
was bolstered by our previous study where pyridoxine 
injection was found to significantly reduce the myelinated 
fibers in the sciatic nerve [25, 26]. NGF therapy is shown 
to significantly prevent the pyridoxine-induced decreases 
in the number of large-sized neurons in the DRG. The 
other 60  % of medium-/small sized neurons can be 
divided into neuropeptidergic and nonpeptidergic groups. 
The neuropeptidergic DRG neurons are easily detected 
by the CGRP antibody, comprising mostly small neu-
rons with unmyelinated axons (C fibers) and innervating 
mainly polymodal nociceptors [44]. SP and CGRP are also 
expressed by a group of medium-sized cells with finely 
myelinated (Aδ) axons, most of which are nociceptors of 
(See figure on previous page.) 
Fig. 6 Substance P (SP) and calcitonin gene‑related peptide (CGRP) immunostaining of the dorsal root ganglion (DRG) in the control (a, b), vehicle‑
treated (vehicle c, d), and nerve growth factor gene‑treated (NGF e, f) groups at 4 weeks after 1 week of pyridoxine injection. In the control group, SP 
immunoreactive neurons are mainly detected in the small‑ and medium‑sized neurons, while CGRP immunoreactive neurons in the small‑, medium‑, 
and large‑sized neurons are well detected in the DRG. Number of SP immunoreactive neurons is similarly detected in all groups, while the number 
of CGRP immunoreactive neurons is decreased in the small‑ and medium‑sized neurons of vehicle‑treated group and this reduction is significantly 
ameliorated in the NGF group. Scale bar = 100 μm. g and h: Relative number as a % of small‑, medium‑, and large‑sized neurons of the control group 
in the DRG (n = 4 per group; *P < 0.05, significantly different from the control group; #P < 0.05, significantly different from the vehicle group). The 
bars indicate the mean ± SEM
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the high-threshold mechanoreceptor type [44]. CGRP has 
important roles in trophic effects in the regeneration of 
peripheral nerves [45] except nociception. In this study, 
the significant reduction of CGRP may be associated with 
impairments of these trophic functions. This result was 
supported by previous study that the number of CGRP-
positive neurons was significantly decreased in type 1 and 
2 diabetic rats compared to their controls [46].
Conclusion
These results suggests that NGF gene therapy protects 
large-sized neurons from pyridoxine-induced injection 
and helps maintain tropic actions in the regeneration of 
peripheral nerves connected to DRG. With this study, we 
conclude that NGF gene therapy in pyridoxine induced 
neuropathic dogs does not induce neuropathic pain and 
facilitates the regeneration of pyridoxine-induced neu-
ropathies in the DRG.
Methods
Animal model
Twelve dogs were used in this experiment, comprising 
6 males and 6 females, each around 2 years of age. Their 
body weights ranged from 4 to 6 kg. All dogs were clinically 
judged to be in good health and neurologically normal. The 
handling and care of the animals was in compliance with 
current international laws and policies (NIH Guide for 
the Care and Use of Laboratory Animals, NIH Publication 
No. 85-23, 1985, revised 1996) and were approved by the 
Institutional Animal Care and Use Committee (IACUC) of 
Seoul National University (Approval no.: SNU-060623-1). 
Dogs were divided into 3 groups; control, vehicle-treated 
and gene therapy group (n = 4 in each group). To induce 
neuropathy, pyridoxine (Sigma, St. Louis, MO, USA) was 
prepared in physiological saline (100 mg/mL) immediately 
before injection, and administered at 150 mg/kg subcuta-
neously, once a day in the morning for 7 days [25] to the 
vehicle-treated and gene therapy groups.
Recombinant dog NGF gene therapy
Twenty-four hours before pyridoxine injection, all of the 
dogs were anesthetized with Zoletil 50® (Virbac, Carros, 
France). Thereafter, depending on the groups to which the 
dogs belonged, a 400 μL vehicle (cationic polymer transfec-
tion reagent, Polyplus transfection, France) or constructed 
recombinant dog NGF plasmid solution (40  μg/400 μL) 
was administered through the intrathecal region using a 
27-gauge needle. The constructed recombinant dog NGF 
plasmid was established in the previous study [26].
Physical examination and postural reaction assessments
Physical examination including respiration rate (nor-
mal range 10–30 breaths/min), heart rate (normal range 
70–180 beats/min), rectal temperature (normal range 
38.0–39.1  °C), systolic arterial blood pressure (normal 
range: 110 mmHg -140 mmHg) and body weight of the 
test dogs were measured every morning during the test 
period. Postural reaction (hopping, wheelbarrowing, 
extensor postural thrust and proprioceptive positioning) 
assessments were also done on all dogs every morning 
during the test period (Table 1 in Appendix) [47].
Electrophysiological recording
At 24  h after the last pyridoxine treatment, all dogs 
were preanesthetized with atropine (0.1 mg/kg of body 
weight, IM). Anesthesia was induced with diazepam 
and was maintained with isoflurane through a semi-
closed system. Subcutaneous temperature was main-
tained at 37–38  °C and Neuropack2 (Nihon Kohden, 
Japan) was used for all recordings. All measurements 
were performed in the left hindlimb and M waves were 
recorded from the tibial nerve, using a 1  Hz, 0.5  ms, 
supramaximal stimulus. Stimulating electrodes were 
positioned at the distal tibial nerve and the recording 
electrode was positioned at the plantar interosseous 
muscle. The ground electrode was positioned between 
the stimulating electrode and the recording electrode. 
The recording electrode was a bipolar needle electrode. 
The Hoffman (H)-reflex was recorded using a 1  Hz, 
0.5 ms, submaximal stimulus. The stimulating electrode 
was positioned at the tibial nerve adjacent to the hook, 
with the recording and ground electrodes positioned at 
the same sites of the tibial nerve where M waves were 
measured. All measurements were performed at least 
eight times. Electrophysiological recordings were per-
formed twice, once before the experiment and once 
after the test period.
Tissue processing
For histological analysis, the dogs were anesthetized with 
a high dose of Zoletil 50® (Virbac, Carros, France) and 
propofol (Myungmoon Pharm., Seoul, Korea), and per-
fused transcardially with 0.1 M phosphate-buffered saline 
(PBS), followed by 4  % paraformaldehyde in 0.1  M PBS 
to induce euthanasia at 4  days after the last pyridoxine 
treatment. After perfusion, tissues from the left and right 
DRG of L4 were quickly removed and post-fixed for 24 h 
in the same fixative at 4  °C. They were then dehydrated 
with graded concentrations of alcohol before being 
embedded in paraffin. Paraffin-embedded tissues were 
serially sectioned using a microtome (Leica Microsys-
tems GmbH, Wetzlar, Germany) into 3-μm sections, 
then were mounted onto silane-coated slides (Muto Pure 
Chemicals Co., Ltd, Tokyo, Japan). The sections apart 
from 150-μm each other were stained with cresyl violet 
according to the standard protocol.
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Immunohistochemistry
The sections apart from 150-μm each other in all groups 
were hydrated and treated with 0.3 % hydrogen peroxide 
(H2O2) in PBS for 30 min. For antigen retrieval, the sec-
tions were placed in 400-mL jars filled with citrate buffer 
(pH 6.0) and heated in a microwave oven (Optiquick 
Compact, Moulinex) operating at a frequency of 
2.45 GHz and an 800-W power setting. After three heat-
ing cycles of 5 min each, slides were allowed to cool to 
room temperature and were washed in PBS. After wash-
ing, the sections were incubated in 10  % normal goat 
serum in PBS for 30 min. They were then incubated with 
rabbit-NGF antibody (1:500; Biorbyt, San Francisco, CA, 
USA), rabbit anti-SP antibody (1:10,000; ImmunoStar, 
Hudson, WI, USA) or mouse-anti-CGRP (1:1,000; 
Abcam, Cambridge, UK) for 48  h at 4  °C. They were 
then exposed to either a biotinylated goat anti-rabbit 
IgG or anti-mouse IgG streptavidin peroxidase complex 
(diluted 1:200, Vector Laboratories, Inc., Burlingame, 
CA, USA), and visualized with 3,3ʹ-diaminobenzidine 
tetrahydrochloride (Sigma) in 0.1  M Tris–HCl buffer 
(pH 7.4).
The number of SP- or CGRP-immunoreactive neurons 
in each group of sections was counted in the DRGs using 
an image analyzing system equipped with a computer-
based CCD camera (software: Optimas 6.5, CyberMet-
rics, Scottsdale, AZ, USA). DRG neurons were separated 
into three categories according to their sizes: small- (area 
1000  μm2), medium- (area 1000–2000  μm2), and large-
sized (>2000 μm2) neurons. The number of these neurons 
in all the groups was counted in the DRG using an image 
analyzing system equipped with a computer-based CCD 
camera (software: Optimas 6.5, CyberMetrics, Scotts-
dale, AZ). Cell counts were obtained by averaging the 
counts from DRG per section (10 sections) under a light 
microscope with a 10× lens.
Statistical analysis
A repeated measure one-way ANOVA test was done for 
the analysis of body weight measurements during the 
experimental period and a t test was done for the electro-
physiological recordings and histochemical results before 
and after the pharmacologic treatment. The level of sig-
nificance was set at p < 0.05.
Additional file
Additional file 1: Figure S1. Nerve growth factor (NGF) immunostain‑
ing of the dorsal root ganglion (DRG) in the vehicle‑treated (A), and NGF 
gene‑treated (B) groups at 4 weeks after 1 week of pyridoxine injection. In 
the vehicle‑treated group, NGF immunoreactive neurons are not detect‑
able in the DRG. In the NGF gene‑treated group, NGF immunoreactive 
neurons are abundantly observed in the DRG. Scale bar = 50 μm.
Abbreviations
CGRP: calcitonin gene‑related peptide; DRG: dorsal root ganglion; H reflex: 
Hoffman‑reflex; NGF: nerve growth factor; rhNGF: recombinant human NGF; 
SP: substance P; trk: tyrosine kinase receptor.
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